Navigation Links
Questcor Pharmaceuticals Issues Statement
Date:1/11/2012

ANAHEIM, Calif., Jan. 11, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ:   QCOR) today announced it became aware that an investor blog is preparing to issue a report regarding the Company's marketing and business practices.  Questcor issued the following statement:

The Company believes that its marketing and business practices are consistent with regulatory requirements and industry standard practices.  Questcor markets H.P. Acthar® Gel for the treatment of acute exacerbations of multiple sclerosis (MS) in adults, the treatment of nephrotic syndrome, and the treatment of infantile spasms in children under two years of age.  The Company maintains a compliance program, which is led by an experienced compliance officer and includes the active participation of Questcor's executive management team.  Questcor attributes its success to the ability of Acthar to potentially address the unmet medical need associated with MS exacerbations and nephrotic syndrome.  The Company is committed to providing access to Acthar to patients who need it, and marketing Acthar in accordance with regulatory requirements and industry standard practices.  Questcor plans to speak with the publication to discuss the Company and its marketing and business practices.

About Questcor                                                                                     

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product, Acthar, helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of nephrotic syndrome, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also exploring the use of Acthar to treat systemic lupus erythematosus, or SLE, for which Acthar is approved as both a maintenance therapy and to treat exacerbations.  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.  In October 2011, Forbes magazine ranked Questcor number one in its annual rankings of America's Best Small Companies.  For more information, please visit www.questcor.com.

 

 


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Reports Solid Fourth Quarter Results
2. Questcor to Discuss Results From FDA Panel Meeting
3. Trading Halted Today in Questcor Pharmaceuticals Common Stock
4. Questcor to Present at the Jefferies 2010 Global Life Sciences Conference
5. Questcor Receives Notification of PDUFA Date Extension to September 11, 2010
6. Mitchell J. Blutt, M.D. Appointed to Questcor Board of Directors
7. Questcor to Present at UBS Global Life Sciences Conference
8. Questcor and Child Neurology Foundation Support the 2nd Annual Infantile Spasms (IS) Awareness Week
9. Questcor Teams With Child Neurology Foundation (CNF) to Fund Infantile Spasms Scientific Research
10. Questcor to Present at the 21st Annual Oppenheimer Healthcare Conference
11. Questcor Reports Third Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2017)... , Aug. 2, 2017 Fenita ... Who as a Pinnacle Lifetime Professional in the ... Account Manager at Turing Pharmaceuticals, AG. Her skills ... and relationship building.                ... than 25 years of experience as a highly ...
(Date:8/2/2017)... 2017 CaryRx, a next-generation full-service pharmacy, has announced ... patients in the Washington D.C. metropolitan ... providing delivery of medications through the convenience of its patient-friendly ... delivered within one hour to any location in D.C. ... this invaluable service to Washington D.C. ," says ...
(Date:7/31/2017)... July 31, 2017 Three Tru-D SmartUVC robots have ... South Korea . Tru-D, short for "Total Room Ultraviolet Disinfection," is ... after an environmental services (ES) professional cleans the area with traditional cleaning ... Tru-D fights ... "Although the BAACH has a ...
Breaking Medicine Technology:
(Date:8/16/2017)... , ... August 16, 2017 , ... Maury Regional Health ... and blood draws. By broadly deploying AccuVein devices, Maury Regional Medical Center is making ... the guesswork out of a needle stick and more importantly, helps our staff members ...
(Date:8/16/2017)... , ... August 16, 2017 , ... A global leader ... successfully opened clubfoot clinics in all 29 Indian states—bringing the country one step closer ... Kangra, Himachal Pradesh, the nonprofit organization is on track to enroll 10,000 children in ...
(Date:8/16/2017)... Atlanta, Georgia (PRWEB) , ... August 16, 2017 , ... ... to distribute premium original programming over four countries and millions of viewers in a ... available to rent or buy On-Demand and fully available on Blu Ray disc in ...
(Date:8/16/2017)... ... 16, 2017 , ... TopConsumerReviews.com recently gave a best-in-class 5 star rating to ... industry in the United States has undergone major changes over the last decade, particularly ... a doctor’s order to get a blood test or other lab work done. Today, ...
(Date:8/16/2017)... ... 16, 2017 , ... First Choice Emergency Room , the largest network ... as the new Medical Director of its Sienna Plantation facility. , “We are ... Sienna Plantation location,” said Dr. Michael (Derek) Caraway, Area Medical Director of First Choice ...
Breaking Medicine News(10 mins):